River BioMedics is a cardiac drug discovery company. We utilize our in-house developed 3D cardiac models for target validation and compound screening in the hit-to-lead stage. The inclusion of these human-predictive assays into our drug discovery pipeline provides a unique opportunity to select, already early in the drug discovery process, those compounds that have a high chance of showing human efficacy in clinical trials. Thereby we aim to increase the success rate of cardiac drug discovery and bring novel drugs to patients more efficiently.
